Abstract
Many neurodegenerative diseases are characterized by cellular deposits such as Abeta, Tau, alpha-synuclein, and huntingtin. The ability to image alpha-synuclein deposits in the human brain is essential to support diagnosis and research for Parkinson's disease. This patent application describes the development of novel small molecules showing high affinity to alpha-synuclein.